NVIDIA is making something on 5nm, and we don't know what it is Read more: https://www.tweaktown.com/news/72034/nvidia-is-making-something-on-5nm-and-we-dont-know-what-it/index.html

Les cookies nous permettent de vous proposer nos services plus facilement. En utilisant nos services, vous nous donnez expressément votre accord pour exploiter ces cookies.En savoir plus OK

Le pdf se trouve ci-dessous. Vous pouvez télécharger le pdf en cliquant à droite.

Revenir à l'accueil

Voir également :

/www/actualite/0-SOMMAIRE-audentia-gestion.fr-actualite.htm

/www/actualite/5CarrefourOnline.htm

/www/actualite/600000-trinidadians-hypertension-diabetes-risk-covid-19.html

/www/actualite/Arnaud-Mercier-Burolab.html

/www/actualite/Arnaud-Mercier-Burolab1.html

/www/actualite/Boston-Globe-Events-Twitter.htm

/www/actualite/COVID-19-IMPACT-ON-OPTICAL-ACRYLIC-SHEET-MARKET.html

/www/actualite/Crepy.html

/www/actualite/Darmanin.html

/www/actualite/EBPenTelechargement.htm

/www/actualite/Etalab-Twitter.htm

/www/actualite/Expedia.html

/www/actualite/Gemo.html

/www/actualite/GroupeLaPoste-Twitter.htm

/www/actualite/Harbin.html

/www/actualite/Institut-Pasteur.html

/www/actualite/Kering.html

/www/actualite/Le-Souvenir-Francais-Twitter.htm

/www/actualite/Les-Francais-n-auront-surement-pas-le-droit-de-changer-de-region-apres-le-11-mai.html

/www/actualite/Les-offres-d-emploi-IT-devissent-de-40-pour-cent-en-un-mois.html

/www/actualite/Micropole.html

/www/actualite/Motorola-Edge.html

/www/actualite/NOUVELLES VERSIONS JANVIER 2013 Remise de 10.htm

/www/actualite/On-pourra-bientot-depenser-95-euros-en-tickets-restaurant.html

/www/actualite/Recherche-Google.htm

/www/actualite/Respirateurs.html

/www/actualite/SF_Siege-Twitter.htm

/www/actualite/TIME-magazine-lauds-role-of-Ghana-s-drones-in-coronavirus-fight.html

/www/actualite/Theradiag.html

/www/actualite/Toyota.html

/www/actualite/VIDEO-Confinement-avec-leur-parodie-de-Jacques-Brel.html

/www/actualite/Vallourec.html

/www/actualite/Videotron.html

/www/actualite/ViralClear-Publishes-Comparative-In-Vitro-Data-on-Merimepodib-and-Remdesivir-Activity-Against-the-COVID-19-Novel-Coronavirus-in-F1000-Research.htm

/www/actualite/actualite.htm

/www/actualite/actualite1.htm

/www/actualite/actualite10.htm

/www/actualite/actualite11.htm

/www/actualite/actualite12.htm

/www/actualite/actualite13.htm

/www/actualite/actualite14.htm

/www/actualite/actualite15.htm

/www/actualite/actualite16.htm

/www/actualite/actualite17.htm

/www/actualite/actualite18.htm

/www/actualite/actualite19.htm

/www/actualite/actualite2.htm

/www/actualite/actualite20.htm

/www/actualite/actualite21.htm

/www/actualite/actualite22.htm

/www/actualite/actualite23.htm

/www/actualite/actualite24.htm

/www/actualite/actualite25.htm

/www/actualite/actualite26.htm

/www/actualite/actualite27.htm

/www/actualite/actualite28.htm

/www/actualite/actualite29.htm

/www/actualite/actualite3.htm

/www/actualite/actualite30.htm

/www/actualite/actualite31.htm

/www/actualite/actualite32.htm

/www/actualite/actualite33.htm

/www/actualite/actualite34.htm

/www/actualite/actualite35.htm

/www/actualite/actualite36.htm

/www/actualite/actualite37.htm

/www/actualite/actualite38.htm

/www/actualite/actualite39.htm

/www/actualite/actualite4.htm

/www/actualite/actualite40.htm

/www/actualite/actualite41.htm

/www/actualite/actualite42.htm

/www/actualite/actualite43.htm

/www/actualite/actualite44.htm

/www/actualite/actualite45.htm

/www/actualite/actualite46.htm

/www/actualite/actualite47.htm

/www/actualite/actualite48.htm

/www/actualite/actualite49.htm

/www/actualite/actualite5.htm

/www/actualite/actualite50.htm

/www/actualite/actualite51.htm

/www/actualite/actualite52.htm

/www/actualite/actualite53.htm

/www/actualite/actualite54.htm

/www/actualite/actualite55.htm

/www/actualite/actualite56.htm

/www/actualite/actualite57.htm

/www/actualite/actualite58.htm

/www/actualite/actualite59.htm

/www/actualite/actualite6.htm

/www/actualite/actualite60.htm

/www/actualite/actualite61.htm

/www/actualite/actualite62.htm

/www/actualite/actualite63.htm

/www/actualite/actualite64.htm

/www/actualite/actualite65.htm

/www/actualite/actualite66.htm

/www/actualite/actualite67.htm

/www/actualite/actualite68.htm

/www/actualite/actualite69.htm

/www/actualite/actualite7.htm

/www/actualite/actualite70.htm

/www/actualite/actualite71.htm

/www/actualite/actualite72.htm

/www/actualite/actualite8.htm

/www/actualite/actualite9.htm

/www/actualite/actualitebandeau728.htm

/www/actualite/actualiteboutiquedutimbre.htm

/www/actualite/biosig-up-10-on-encouraging-data-on-covidminus-19-antiviral.htm

/www/actualite/colissimo.htm

/www/actualite/cookiechoices.js

/www/actualite/farnell-Imbattable.htm

/www/actualite/farnellactualitebandeau728.htm

/www/actualite/fnacactualitebandeau728.htm

/www/actualite/gilead-says-draft-of-coronavirus-treatment-results-contain-inappropriate-characterization-and-are-inconclusive.html

/www/actualite/gouvernementFR-Twitter.htm

/www/actualite/grosbillactualitebandeau728.htm

/www/actualite/hypertension-patients-diabetics-at-high-risk-for-covid-19.html

/www/actualite/loutremer-Twitter.htm

/www/actualite/maillot-collector-de-Thibaut-Pinot.html

/www/actualite/particulier-vend-51-m2-VERSAILLES.htm

/www/actualite/planetencre.htm

/www/actualite/sinscrirenewsletter.htm

/www/actualite/sitemapactualite.xml

/www/actualite/telecharger.php

/www/actualite/tetherless-pulse-oximeter-can-monitor-covid-19-patients-home.html

Au format texte :

Technology and gaming content trusted in North America and globally since 1999 8,575 Reviews & Articles | 60,314 News Posts CORONAVIRUS NEWS REVIEWS ARTICLES GUIDES GAMING ASK THE EXPERTS NEWSLETTER FORUMS Cases, Cooling & PSU CPUs, Chipsets & SoCs Motherboards Peripherals RAM Storage Video Cards Home News Video Cards NVIDIA is making something on 5nm, and we don't know what it is NVIDIA's mysterious 5nm product probably isn't a next-gen GPU, but TSMC is making something for Team Green on 5nm Anthony Garreffa | Apr 23, 2020 at 10:47 pm CDT (0 mins, 45 secs time to read) So, NVIDIA is making something on a fresh new 5nm node -- ordering TSMC to make it for the GeForce giant. Digitimes is reporting from its "industry sources" that NVIDIA is tapping TSMC's fresh new 5nm process node -- and it won't be for NVIDIA's next-gen Ampere GPU architecture or the GeForce RTX 3080 and GeForce RTX 3070 graphics cards. There is absolutely nothing else to this news other than Digitimes reporting that its sourcesh ave told them, that NVIDIA is making something new and mysterious on TSMC's new 5nm process node. It could be something for the Tegra side of things, or here's a wild rumor -- so prepare your salt shakers peeps -- the Nintendo Switch 2 SoC. Just throwing that out there. ASUS ROG STRIX GeForce RTX 2080TI Overclocked (ROG-STRIX-RTX-2080TI-O11G) Today Yesterday 7 days ago 30 days ago $1279.99 $1279.99 $1279.99 $1279.99 Buy * Prices last scanned on 4/23/2020 at 10:47 pm CDT - prices may not be accurate, click links above for the latest price. We may earn an affiliate commission. NEWS SOURCES:tomshardware.com, digitimes.com, s.thestreet.com ABOUT THE AUTHOR - Anthony Garreffa Anthony is a long time PC enthusiast with a passion of hate for games built around consoles. FPS gaming since the pre-Quake days, where you were insulted if you used a mouse to aim, he has been addicted to gaming and hardware ever since. Working in IT retail for 10 years gave him great experience with custom-built PCs. His addiction to GPU tech is unwavering. Similar News TSMC making 5nm ASICs for Bitmain and Canaan in 2020 AMD's next-gen Zen 4 could arrive on new 5nm or 6nm in 2021 TSMC makes progress on 5nm, should have 5nm chips in 2020 Intel promises process node leadership with 5nm... but in 2022+++ Apple's new iPhone will be powered by A14 chip made on 5nm from TSMC < PREVIOUS STORY: Intel's upcoming Ponte Vecchio Xe GPU turns up in add-in card form Related Tags NVIDIA TSMC 5nm NVIDIA 5nm node NVIDIA 5nm tech TSMC 5nm Nintendo Newsletter Subscription Latest News NVIDIA is making something on 5nm, and we don't know what it is Intel's upcoming Ponte Vecchio Xe GPU turns up in add-in card form NVIDIA, AMD purchase ALL excess capacity at TSMC for next-gen GPU/CPUs Intel revenue up 23% to $19 billion in Q1, operating income spikes 69% PlayStation 5 may use vapor chamber cooling, new Sony patent suggests View More News Latest Reviews Synology DS220j Two-Bay Consumer NAS Review ARCTIC Liquid Freezer II 280 CPU Cooler Review NZXT C850 Gold ATX Power Supply Review Seagate IronWolf 510 m.2 NAS SSD Review Star Wars: The Rise of Skywalker 4K Blu-ray Review View More Reviews Latest Articles GeForce Ti Showdown: GTX 980 Ti vs GTX 1080 Ti vs RTX 2080 Ti Best Gaming Monitors in 2020 (4K, UltraWide, 1440p, and 1080p) Best GPUs for PC Gaming in 2020 DOOM Eternal Benchmarked at 8K - Not Even The Devil Can Run This Half-Life: Alyx Buyers Guide: PC Hardware & VR Headset Recommendations View More Articles SITEMAP ADVERTISING ABOUT CONTACT RSS FEEDS PRIVACY POLICY © 1999-2020 Tweak Town Pty Ltd. All Rights Reserved. Read more: https://www.tweaktown.com/news/72034/nvidia-is-making-something-on-5nm-and-we-dont-know-what-it/index.html Search Reviews Smart Home & Gadgets Mobile Car Tech Online Science & Health Cameras Computing Gaming Entertainment Apple iPhone SE: Australian First Look Review Apple's iPhone SE: Every Phone Plan In Australia Every Telstra Plan For The New iPhone SE Apple iPhone SE: Australian First Look Review Tegan Jones | Apr 24, 2020, 2:25pm⋅ Filed to: apple Share Image: Tegan Jones/Gizmodo Australia Last year, Google turned the mid-range phone market on its head by introducing the ludicrously-priced and well-specced Pixel 3a. A few other brands have followed suit since then, but none have been quite as exciting as the new iPhone SE. Now it truly seems like flagship inclusions at lower price points are here to stay - and it's about damn time. The trend of $1,500 - $2,000 becoming the norm for new phones over the last few years has been bad for buyers. A new middle ground has been long overdue and we welcome it. But is the resurrected iPhone SE actually a good phone to buy in 2020? It's worth noting that I have only been playing with the iPhone SE for a day and a half, so these are my first impressions. Keep your eyes peeled for the full review next week. iPhone SE Specs But before we dive into things, here's a quick reminder of the specs. Display: 4.7 inches (1334 x 750) CPU: A13 Bionic Chip Storage: 64GB, 128GB, 256GB Battery: Up to 13 hours video playback, Qi wireless charging, fast charge Rear camera: 12MP (f/1.8) Front camera: 7MP (f/2.2) Video recording: 4K video up to 60 fps Water resistance: IP67 Size: 5.45 x 2.65 x 0.29 inches Weight: 148g Colour: Black, White, PROJECT(RED) iPhone SE Price In Australia In Australia the iPhone SE starts at $749 for the 64GB. 12GB will bring the price up to $829 and 256GB comes in at $999. You can grab one from the Apple Store now. If you'd prefer a plan, we have all of them compiled in one handy place for you. What's good about the iPhone SE? The iPhone SE is such a good size for smaller hands. Image: Tegan Jones/Gizmodo Australia iPhone SE Size In a world where 6.5-inch phones have become par for the course, it's refreshing for a premium phone manufacturer to offer something a bit smaller. While large phones screens are good for some things – streaming shows, reading, general browsing – they can also be incredibly uncomfortable. While I have gotten used to the iPhone 11 Pro Max, I have found the SE far more comfortable to use as a daily driver. The screen size isn't too small, the device nestles perfectly into my hand and it can actually fit into my lady pockets. A true miracle in 2020. And from a tactile perspective, it's the same as flagship phone – you won't find cheap plastic here. The material is lovely to touch and feels exactly the same as my 11 Pro Max, just smaller. While it isn't as small as the previous SE or some other older iPhones, I think that anyone upgrading from one of those previous generations will still be pleased – especially if you compare it to something like the Pro or Pro Max. iPhone SE Camera I'll have a far more in-depth dive into the iPhone SE camera in my full review, but I have a few initial thoughts. It's important to set your expectations if you're coming to the SE from a flagship device. It only has a single lens on the front and back, so it simply can't have the same functionality as a triple or quad camera array. That being said, it still pretty darn good so far, and this is primarily due to the processor. The iPhone SE has the same A13 bionic chip as iPhone 11 devices, which is a crazy move that I'm here for. The signal processor and N=neural engine in the A13 boosts the computational photography of the iPhone SE, which helps make up for what it lacks in hardware. But what does that actually mean when it comes to real world functionality? To put it simply, the single camera lenses are more capable thanks to the processor and software. The SE has Smart HDR, optical image stabilisation, subject recognition and the ability to capture clearer faces. It's also able to offer the same six lighting affects in portrait mode as the iPhone 11, as well as depth control adjustment you usually need a second lens for. When it comes to video, the rear camera is still able to capture 4K and 30 fps with cinematic stabilisation. As for the selfie cam, you still get the lovely bokeh effect – the soft, out-of-focus background in photos – of pricier iPhones thanks to the inclusion of monocular depth estimation. So far I have mostly messed around with the portrait and regular photo modes - and they really do a great job for single lenses. Sure, they're not as good as the iPhone 11 Pro Max, but at a price point of $750 - $1000 that was never going to happen. Here are a few comparisons between the iPhone SE and iPhone 11 Pro Max: iPhone SE Regular Photo Mode There's a noticeable different between the iPhone SE (left) and iPhone 11 Pro Max (right) in terms of brightness, sharpness and warmth. However, some of this could be brought back into the final product with some editing. iPhone SE Portrait Mode Left: iPhone SE, Right: iPhone 11 Pro Max iPhone SE Low Light Camera The iPhone SE (left) doesn't have a dedicated night mode like the iPhone 11 Pro Max (right) but it's low-light capabilities seem quite decent so far. iPhone SE Selfies Left: iPhone SE, Right: iPhone 11 Pro Max If you want to best camera phone on the market, the iPhone SE is not what you should opt for. But so far, I'm quite impressed and I'm looking forward to putting it through its paces more. What's not so good about the iPhone SE? Image: Tegan Jones/Gizmodo Australia iPhone SE Battery Life Unlike Android manufacturers, Apple doesn't reveal its battery sizes - but we do know that it's smaller than any device in the iPhone 11 lineup. For example, Apple quotes the SE as having up to 13 hours of video playback, where as the baseline iPhone 11 has up to 17. It didn't take long for me to notice the battery drain, particularly when I went out for a walk. In 30 minutes, the battery dropped by 13 per cent while I had my AirPods Pro connected via bluetooth, location enabled and Spotify playing. During that time I also sent some messages via Facebook Messenger and Slack. I went on a similar walk the next day and lost 10 per cent battery in 20 minutes - this time around I had added some light browsing into the mix. That being said, the battery still go me through the whole day. I started using the device at 7:30am and by 11:30pm it was down to 3 per cent. As a moderate to heavy user, this was okay. However, if Australia wasn't in lockdown right now I would probably have run out of battery earlier due to heavier music listening and reading on my morning commute, as well as connecting my Apple watch for gym workouts and taking the phone out after work. If the world was normal right now, I would definitely need to be put the SE on a charger during the day. Apple's iPhone SE: Every Phone Plan In Australia Apple mic-dropped the mobile world last week by unveiling a brand new iPhone SE for just $749. Not only that, even the most expensive version of the mid-range phone still comes in at under $1000. The phone is on sale today, and every major Aussie telco is on board with this little beauty. Because opening 500 tabs to compare phone plans sucks, we have rounded up all of them for you. You're welcome. Read more But despite my battery complaints, it's important to take my own experience and background into account. I review phones for a living and use an iPhone 11 Pro Max regularly. And in recent weeks, I've been playing around with the Samsung S20 Ultra and Huawei P40. These are flagship phones with huge batteries. My prediction is that people most likely to buy an iPhone SE will be upgrading from an older Apple device, such as an iPhone 6, 7 or 8. Alternatively, they're low to moderate phone users who simply want a cheaper device without having to make a lot of compromises. If these scenarios sound like you, the battery life on the iPhone SE will be just fine. You'll probably find that it's on par with the iPhone 8 and still larger than anything older than that – especially when you take battery degradation into account. Plus, the iPhone SE charges incredibly quickly thanks to 30W fast-charge capabilities, combined with the smaller battery. I even found that the wireless charging on it was quite speedy. If you want a more robust battery, you should consider upgrading to an iPhone 11 or 11 Pro instead. But if you don't mind something a bit smaller, the iPhone SE could be likely be perfect for you. iPhone SE Bezel While this isn't a problem for me, this will probably bug some people. So let's talk about it. The 4.7-inch display has quite a thick bezel at the top and bottom of the device to house the home button and front-facing camera. This makes sense because it would cost a lot more to include an in-screen fingerprint reader and camera. However, some folks may not like how this throwback inclusion eats into the screen real estate, especially if they enjoy streaming content on their phones. While it's not my favourite feature, the bezels really don't bother me that much and after a few days of use I don't really miss Face Unlock. I also found watching Netflix and Quibi on the SE great. The smaller screen didn't bother me and the brightness and quality of the display was lovely. However, if you're a fan of having as much screen as possible, it's probably worth considering one of the Phone 11 models instead. Is the iPhone SE Worth It? Image: Tegan Jones/Gizmodo Australia I've only had the iPhone SE in my hot little hands for a couple of days, so I'll hold my hard stance recommendations until my full review. That being said, this is a great device for the price point – even if you are still paying a premium because it's Apple. While it doesn't have all the bells and whistles of the more expensive iPhones, there's more than enough of them to be perfect for some people. At the same time, it still offers some flagship features you usually have to pay more for, so it's future proofed for a few years. Qi wireless charging, eSIM functionality and water resistance are all fantastic inclusions – but the real game changer here is the A13 bionic chip. Being able to get the best phone processor on the market in a sub-$1000 phone is a real power move by Apple, and one that will probably pay off for them. The iPhone SE is as modern as it is thoughtful. It provides an option for people on a tighter budget or who don't want to stretch their fingers across the mammoth phone screens that have become the norm over the last few years. Trending Stories Right Now apple au feature iphone-se Apple iPhone SE: Australian First Look Review Tegan Jones 24 Apr 2020 2:25 PM Last year, Google turned the mid-range phone market on its head by introducing the ludicrously-priced and well-specced Pixel 3a. A few other brands have followed suit since then, but none have been quite as exciting as the new iPhone SE. Now it truly seems like flagship inclusions at lower price points are here to stay - and it's about damn time. The trend of $1,500 - $2,000 becoming the norm for new phones over the last few years has been bad for buyers. A new middle ground has been long overdue and we welcome it. But is the resurrected iPhone SE actually a good phone to buy in 2020? books chang-chen charlotte-rampling denis-villeneuve dune frank-herbert io9 jason-momoa javier-bardem josh-brolin oscar-isaac rebecca-ferguson stellan-skarsgard timothee-chalamet warner-bros zendaya A Guide To Dune's Gargantuan Cast Of Characters Beth Elderkin 24 Apr 2020 1:02 PM This could be the biggest movie event of 2020—and we mean that literally. There are so many characters in Dune that it’s hard to keep them straight. We’ve got a handy guide to the biggest characters in Denis Villeneuve’s adaptation (with as few spoilers as possible) and who’s playing them, as well as a few others we hope to see in the sequel. Want Gizmodo's email newsletter? Enter your email address Follow us, subscribe and get in touch! Latest Deals Deals: $300 Off Samsung Galaxy S20 5G And S20+ 5G Phones The Fastest NBN Providers According To Netflix Dayum, Telstra Just Doubled The Data Of Its Cheapest Plan Tell Us How You're Coping With The Coronavirus Epidemic And You Could Win A $500 Uber Eats Voucher Trending Articles 1Apple iPhone SE: Australian First Look ReviewApple iPhone SE: Australian First Look Review 231 Little-Known Settings On Your Phone And Laptop You Should Know About31 Little-Known Settings On Your Phone And Laptop You Should Know About 3A Guide To Dune's Gargantuan Cast Of CharactersA Guide To Dune's Gargantuan Cast Of Characters Here’s What You Oughta Know About Grabbing Cash Out Of Your Super During The PandemicI Looked Up Foot Fetish Porn For A Lol But Now It’s The Only Thing That Gets Me OffThese Embarrassing As Hell Work Stories’ll Make You Clench For EternityI Genuinely Fear For My Social Skills Once Iso Is Over & We Have To, You Know, Interact Battlefield V Set For Final Content Drop As Development Shifts To SequelIndie Developers Are Keeping The PlayStation Vita AliveRevenge Of The Cartels, Mayhem 2.0, Loot The Universe Now Available In Borderlands 3All The Bugs And Fish Leaving Animal Crossing: New Horizons In April Send Packages To Nearby Friends Using Uber ConnectThe Best Recipes For ANZAC Day BiscuitsReminder: No ANZAC Day Long Weekend For Most Of Us This YearWhat Is Dalgona Coffee? The 26 best players still available after the first round of NFL draftGreen Bay Packers pull off one of the biggest surprises of the draft, trading up to draft quarterback Jordan Love as a possible successor to Aaron RodgersFitness Australia says gyms should be reopened if they follow strict guidelines – but an expert says the conditions aren't right 'just yet'Singapore's richest man is getting $1 billion richer each month from selling ventilators © 2007-2020 Pedestrian GroupAboutAdvertiseContactTerms of UseGizmodo International Sign up for Gizmodo Australia's breaking news alerts and get the best stories straight away AllowClose SKIP NAVIGATION BREAKING Oil rallies more than 40% in two days as it comes back from record lows logo SIGN IN PRO WATCHLIST MAKE IT SELECT USA INTL logo MARKETS BUSINESS INVESTING TECH POLITICS CNBC TV SEARCH QUOTES HEALTH AND SCIENCE Gilead says draft of coronavirus treatment results contain ‘inappropriate characterization’ and are ‘inconclusive’ PUBLISHED THU, APR 23 20201:22 PM EDTUPDATED MOMENTS AGO Berkeley Lovelace Jr. @BERKELEYJR KEY POINTS Gilead shares fell after a report, citing a draft document, said antiviral drug remdesivir did not improve Covid-19 patients’ condition or reduce the virus’ presence in the bloodstream in a phase 3 clinical trial. Gilead said the document contained “inappropriate characterizations” and that the study’s findings were “inconclusive.” AP: Gilead Sciences 150709 In this July 9, 2015, file photo, a man walks outside the headquarters of Gilead Sciences in Foster City, Calif. Eric Risberg | AP Gilead Sciences said that a draft document showing disappointing results from a closely watched clinical trial of the company’s treatment for the coronavirus contained “inappropriate characterizations” and that the study’s findings were “inconclusive.” Shares of the biotech firm fell 4% in intraday trading Thursday after the Financial Times reported that antiviral drug remdesivir did not improve Covid-19 patients’ conditions or reduce the virus’ presence in the bloodstream in a clinical trial in China. The report, citing a draft document that was accidentally published by the World Health Organization and has since been removed, also said the drug showed significant side effects, and some patients were taken off of it. “We regret that the WHO prematurely posted information regarding the study, which has since been removed. The investigators in this study did not provide permission for publication of results,” a Gilead spokesperson said in a statement to CNBC. “Furthermore, we believe the post included inappropriate characterizations of the study. Importantly, because this study was terminated early due to low enrollment, it was underpowered to enable statistically meaningful conclusions,” according to Gilead. “As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.” VIDEO00:30 Gilead halted after report Remdesivir flopped in coronavirus trial There are no proven therapies to treat Covid-19, which has infected more than 2.6 million worldwide and killed at least 183,820 as of Thursday, according to data compiled by Johns Hopkins University. U.S. health officials say producing a vaccine to prevent Covid-19 will take at least 12 to 18 months, making finding an effective drug treatment soon even more crucial. There a number of ongoing studies testing Gilead’s remdesivir to see if it’s effective in stopping the coronavirus from replicating. Last week, Gilead surged after details leaked of one of its clinical trials, showing what appeared to be promising results in treating the disease. The University of Chicago found that patients with Covid-19 had “rapid recoveries in fever and respiratory symptoms” and were discharged in less than a week, according to STAT News. The recent swings in Gilead shares over the past week show just how difficult it is to bet on developments for treatments for the coronavirus. Mike Bailey, director of research at FBB Capital Partners and a former health-care analyst at Stifel, told CNBC last week that retail investors are “hungry” for good news on the virus. Those investors could be taking that and channeling it into buying shares, he said. “You could argue [Gilead] buyers are hungry for good news while Moderna buyers are starving for it,” said Mike Bailey, referring to Moderna’s coronavirus vaccine currently in human trials. Remdesivir has shown some promise in treating SARS and MERS, which are also caused by coronaviruses. Some health authorities in the U.S., China and other parts of the world have also been using remdesivir, which was tested as a possible treatment for the Ebola outbreak, in hopes that the drug can reduce the duration of Covid-19 in patients. Results from a Gilead clinical trial involving patients with severe cases of the virus are expected later this month, while data on a trial testing patients with moderate symptoms is expected in May. Infectious disease experts and analysts caution the severe study is “single-arm,” meaning it will not evaluate the drug against a group of patients who didn’t receive the drug. TRENDING NOW Jamie Black-Lewis received loans from the Paycheck Protection Program for her two spas, Oasis Medspa & Salon and Amai Day Spa, in Washington state. Many of her 35 employees think they will make more money collecting unemployment benefits than from their regular paychecks. She got a forgivable Paycheck Protection Program loan. Her employees hate her for it. Remember what this felt like? People enjoy the warm spring weather at Hornstull in Stockholm on April 21, 2020, during the new coronavirus COVID-19 pandemic. Sweden resisted a lockdown, and its capital Stockholm is expected to reach ‘herd immunity’ in weeks New York Governor Andrew Cuomo (D) speaks during a press Conference at the State Capitol. Cuomo rips McConnell’s ‘really dumb’ suggestion to let states declare bankruptcy over coronavirus Treasury Secretary Steven Mnuchin speaks during the daily briefing on the novel coronavirus, COVID-19, in the Brady Briefing Room at the White House on April 2, 2020, in Washington, DC. US issues new guidance for small business loans, pressures public companies to return funds New York Governor Andrew Cuomo (D) speaking at a press Conference at the State Capitol reporting on the latest development of the Covid-19 Coronavirus situation. New York antibody study estimates 13.9% of residents have had the coronavirus, Gov. Cuomo says by TaboolaSponsored LinksFROM THE WEB Si tu aimes jouer, ce jeu de construction de ville est pour toi. Pas d’installation. 14 215 876 y jouent ! Forge Of Empires - Jeu en ligne gratuit Programme Photovoltaique - Originale Gratuit & Sans Engagement logo Subscribe to CNBC PRO Licensing & Reprints CNBC Councils Supply Chain Values Advertise With Us Join the CNBC Panel Digital Products News Releases Closed Captioning Corrections About CNBC Internships Site Map AdChoices Careers Help Contact News Tips Got a confidential news tip? We want to hear from you. GET IN TOUCH CNBC Newsletters Sign up for free newsletters and get more CNBC delivered to your inbox SIGN UP NOW Get this delivered to your inbox, and more info about our products and services. Privacy Policy|Do Not Sell My Personal Information|Terms of Service © 2020 CNBC LLC. All Rights Reserved. A Division of NBCUniversal Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Market Data Terms of Use and Disclaimers Data also provided by Reuters We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences. By using the site, you consent to these cookies. For more information on cookies including how to manage your consent visit our cookie policy. CONTINUE Search by symbol, author, keyword... Sign in Marketplace Subscribe Premium My Portfolio Authors Top Stocks Latest News Markets Stock Ideas Dividends ETFs Investing Strategy Podcasts Help & Support Healthcare | On the Move BioSig up 10% on encouraging data on COVID-19 antiviral Apr. 23, 2020 9:49 AM ET|About: BioSig Technologies, Inc. (BSGM)|By: Douglas W. House, SA News Editor BioSig Technologies (BSGM +10%) is up out the gate on the heels of results from laboratory studies comparing the antiviral activity of subsidiary ViralClear's merimepodib to Gilead Sciences' (GILD +2.2%) remdesivir. Cell cultures were pretreated with two concentrations of either merimepodib or remdesivir for four hours before SARS-CoV-2 virus was added. At hour 16, both concentrations of the former and the higher concentration of the latter significantly reduced viral production. At hour 24, both concentrations of both drugs significantly reduced viral production. Additional studies are underway. ViralClear intends to launch clinical trials in COVID-19 next quarter (assuming FDA sign-off). Merimepodib is a broad-spectrum antiviral that Vertex Pharmaceuticals (VRTX +1.5%) was originally developing for hepatitis C and psoriasis. See all stocks on the move » 413 people get BSGM breaking news and analysis by email alert Get email alerts on BSGM Recommended for you: DoctoRx Why Gilead's COVID Drug May Be The Magic Bullet We Need DoctoRx • Apr. 19, 2020 11:06 PM ET WG Investment Research Bank Of America: This Time Will Be Different, Seriously WG Investment Research • Apr. 23, 2020 8:10 PM ET Wall Street Breakfast Wall Street Breakfast: First Oil Major To Cut Dividend Wall Street Breakfast • Apr. 23, 2020 1:00 PM ET Robert & Sam Kovacs Johnson & Johnson: I Don't Want To Say I Told You So Robert & Sam Kovacs • Apr. 22, 2020 7:38 PM ET Eric Parnell, CFA The Bear Is On The Prowl Eric Parnell, CFA • Apr. 23, 2020 4:34 PM ET Comments 9 • Sort by Add Your Comment User 50681444 Comments27 | + Follow He is a very smart man , it would be smart fro Trump to own it. It was just proved to work better than the biggest hopeful Remdesivir in lab test! And , this is the kicker - This drug is in pill form which means that the patient can take it at home!!! This stock is going to blow up !!! Buy it while you can! 23 Apr 2020, 01:15 PMReply0Like Rudester Comments5178 | + Follow Anybody knows if Trump owns stock in this one, like he does in the largest maker of hydroxychloroquine? 23 Apr 2020, 11:32 AMReply1Like alphaseek2018 Comments1514 | + Follow Yes he has a $99 holdings in hydroxychloroquine maker. Give me a break! 23 Apr 2020, 12:55 PMReply1Like 6x7 bigelk Comments74 | + Follow Go INO go 23 Apr 2020, 11:20 AMReply0Like Oil Can Comments2739 | + Follow Good news. We need to move forward to clinical trials every drug that has potential against COVID-19. This will not be a one-and-done game; we need to have multiple candidates under evaluation until a clear winner - or winners - emerge. As I understand it, once we have a viable therapeutic, there is the possibility of accelerating vaccine trials. 23 Apr 2020, 10:46 AMReply0Like APB Comments881 | + Follow So this new treatment might be ready to go in 3 or 4 years? If 20% of the population does in fact already have antibodies for COVID 19 then it will probably be obsolete before it reaches phase 2 trial? 23 Apr 2020, 10:43 AMReply0Like Matt-Man Comments2983 | + Follow Getting safety profile would take year alone, maybe 7-10year if lucky. Also HydroChloroquine had great in-vintro results 23 Apr 2020, 10:58 AMReply1Like Todd Kenyon, CFA Comments326 | + Follow This is in a culture - so far from being approved. I could dump Clorox in that culture and it would kill the virus too. The hcq jury is still out as the negative results were just one crappy anecdotal study with many issues. As were the positive ones. We don’t know yet bottom line. 23 Apr 2020, 10:18 AMReply9Like LilKleine Comments18 | + Follow Some good news after the disappointing results from the hydroxychloroquine study 23 Apr 2020, 10:02 AMReply0Like RSS Feeds|Advertise with Us|Sitemap|About Us|Feedback|Careers|Contact Us Terms of Use|Privacy|Market Data Disclaimer|© 2020 Seeking Alpha GlobeNewswire Intrado Logo Search REGISTER SIGN IN ENGLISH FRANÇAIS CONTACT US GLOBAL DISTRIBUTION NEWSWIRE SERVICES REGULATORY FILINGS MEDIA PARTNERS Bio-Sig-Logo-horiz.jpg ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research Email Print Friendly Share April 23, 2020 09:15 ET | Source: BioSig Technologies, Inc. Westport, CT, April 23, 2020 (GLOBE NEWSWIRE) -- Merimepodib is shown to decrease viral production of COVID-19 coronavirus more than remdesivir at clinically meaningful drug concentrations in pre-clinical testing. Article highlights recent work done in laboratory studies of COVID-19 with merimepodib at the Galveston National Laboratory at The University of Texas Medical Branch BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, “The IMPDH inhibitor merimepodib has similar antiviral activity against SARS-CoV-2 replication in vitro to the adenosine analogue remdesivir” was accepted by F1000 Research, an online peer-reviewed life sciences journal publishing program in biology and medicine. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author. The article highlights emerging pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. The work was started with Trek Therapeutics and after merimepodib was acquired by ViralClear has been continued by ViralClear. “The concentrations of merimepodib used in the cell culture studies described in this article are achievable in humans by our oral solution formulation,” said Dr. Zeldis, Executive Chair and Founder of ViralClear Pharmaceuticals, Inc. “We are now exploring whether remdesivir and merimepodib are synergistic in this in vitro model. We look forward to starting our first clinical trial in COVID-19 patients upon receiving FDA clearance to commence with the proposed phase 2 trial.” Vero cells in tissue culture were pre-treated with two concentrations (2.5 and 5 µM) of either merimepodib or remdesivir for 4 hours before the SARS-CoV-2 coronavirus was added. The amount of virus released to the media was measured at baseline and 16 hours and 24 hours after infection. At 16 hours, a significant reduction in viral production was observed for both concentrations of merimepodib (1.9 log decrease in titer, p = 0.003 and 2.1 log decrease in titer, p = 0.001) but only at the higher concentration of remdesivir (1 log decrease in titer, p = 0.103 and 2.1-log decrease in titer, p = 0.001). At 24 hours both concentrations of both drugs significantly reduced viral production; however, 2.5 µM remdesivir reduced viral titer by 1.5 logs (p = 0.002) as compared to a decrease of 3.9 logs for 5 µM remdesivir (p < 0.001), whereas 2.5 and 2.7 log reductions (p = 0.001 and p < 0.001, respectively) were observed for the 2.5 and 5 µM concentrations of merimepodib. Merimepodib, a broad-spectrum anti-viral candidate, demonstrated strong activity against COVID-19 in cell cultures in laboratory testing and additional antiviral studies are underway. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with a 12 clinical trials conducted (including 315 chronic hepatitis C patients, 24 psoriasis patients, and 98 healthy volunteers) and an extensive preclinical safety package completed . ViralClear intends to pursue development of this agent for the treatment of COVID-19 through FDA-approved clinical trials in Q2 2020. About BioSig Technologies BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com). The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. About ViralClear BioSig’s subsidiary ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical to treat advanced COVID-19. Merimepodib is a broad-spectrum anti-viral agent that has demonstrated strong activity against the COVID-19 virus in cell cultures in laboratory testing. ViralClear plans to initiate a multi-center, phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of merimepodib administered orally every eight hours for 10 days in adult patients with advanced COVID-19 upon FDA clearance to proceed. Merimepodib has been studied in twelve clinical trials prior to this study, including five trials in patients with hepatitis C (one phase 1b, one phase 2, two phase 2a, and one phase 2b), one trial in patients with psoriasis (phase 2), and six trials in healthy volunteers (all phase 1). Forward-looking Statements This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133 Related Articles More articles issued by BioSig Technologies, Inc. More articles related to: Company Announcement Profile BioSig Technologies, Inc. Subscribe via RSS Subscribe via ATOM Javascript Westport, Connecticut, UNITED STATES Contact Data Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133 Contact Biosig Technologies (BSGM) Intraday 3 Month 6 Month 1 Year Last: $7.50 Change: +0.30 % Change: +4.17% Volume: 1M Open: $7.14 Previous Close: $7.20 Low: $7.14 High: $8.32 Market Cap: 0 Shares Outs.: 0 EPS: 0.00 P/E Ratio: - Dividend: N/A Yield: N/A 52 Week Low: $2.36 52 Week High: $9.97 Quote delayed at least 20 mins. Media Files Bio-Sig-Logo-horiz.jpg Logo Download Options Bio-Sig-Logo-horiz.jpg LOGO URL | Copy the link below http://www.globenewswire.com/attachment-download-view/2021020/564767/4/1/0/564767.jpg Tags HEALTHMEDICALelectrophysiologystocknasdaqdeviceinvestorarrhythmiaAfibVTheartEPscienceablationbioelectronic medicine Related Links https://www.biosig.com/ Newswire Distribution Network & Management Home Newsroom RSS Feeds Legal About Us GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public. © 2020 GlobeNewswire, Inc. All Rights Reserved. Trinidad and Tobago Newsday News Latest Sports Sections N Touch NEWS Hypertension patients, diabetics at high risk for covid 19 RYAN HAMILTON-DAVIS 4 HRS AGO File photo - File photo - The elderly are not the only people especially at risk for contracting covid19. People with hypertension, diabetes and kidney disease are also at high risk. So said Dr Neil Bhagwandass, nephrologist at San Fernando Hospital, at the Wednesday's covid19 update at the Ministry of Health headquarters on Park Street in Port of Spain. He listed the categories of people especially susceptible to the disease, which also included people who have suffered strokes or who have had lung diseases. Trendingview all 1 Designer defends $75, $100 cloth masks after backlash NARISSA FRASER 2 SORT foils alleged murder plot SHANE SUPERVILLE 3 Two held in Barrackpore after chase, 2 on the run LAUREL V WILLIAMS 4 Deyalsingh: Suspected case at step-down facility SHANE SUPERVILLE 5 Judge orders couple’s release JADA LOUTOO 6 ‘Stay at home’ challenged JADA LOUTOO 7 Brother, sister gunned down at home LAUREL V WILLIAMS Comments "Hypertension patients, diabetics at high risk for covid 19" More in this section NEWS Msgr Pereira: Spread Muslim fast to other religions YVONNE WEBB NEWS Corporations get $1m each to fight covid19 YVONNE WEBB NEWS CoP calls on public: Give info to reduce murders SHANE SUPERVILLE NEWS Attorney: People may sue over roadblocks SEAN DOUGLAS Trinidad and Tobago Newsday© 2020 Trinidad and Tobago Newsday. N Touch About Us Staff Classifieds Advertise Privacy Policy Contact Us Share to Facebook Share to WhatsApp Share to Twitter Share to Email Share to Print More AddThis Share options Skip to main content Thursday 23 April, 2020 Loop Market Trinidad And Tobago Home Search T&T News World News COVID-19 Carnival Viral Entertainment Lifestyle Business Sport BREAKING NEWS | Over 300,000 with hypertension at higher COVID-19 risk, says Minister ALINA DOODNATH CREATED : 23 APRIL 2020COVID-19[iStock.com/FatCamera] [iStock.com/FatCamera] Thousands of Trinidadians with diabetes and hypertension are at a higher risk due to the novel coronavirus (COVID-19), which if it spreads, ‘could be a disaster’, according to the Health Ministry. Speaking at Thursday’s media briefing to update the public on COVID-19 measures, Health Minister Terrence Deyalsingh said 341,000 people were diagnosed with hypertension, according to Ministry statistics – 23.6 percent of the population. He added that 266,000 (20.5 percent) of the population suffer from diabetes, saying that the figure is probably an underestimation as many people may not be aware they have diabetes. Dr Neal Bhagwandass, Nephrologist and Acting Head of Department, Medicine, at the San Fernando General Hospital, said it is critical that dialysis patients do not contract or spread the virus when receiving treatment. He said there are approximately 1,400 patients receiving hemodialysis treatments through the public health care system. "A typical dialysis would have 20-30 patients dialysing at one time. Our nephrologists have instituted policies so that patients are not allowed to congregate. Patients should be kept at least six feet apart and as soon as the dialysis procedure is finished they are to leave the environment." He said dialysis patients are screened on entering and are asked about any flu-like systems. "If we have to swab, swab them because this is a very high-risk population...we do not want COVID-19 to spread among our dialysis population, that could be a disaster." Dr Bhagwandass said those patients can experience kidney failure if they were to contract the virus. Dr Bhagwandass said diabetic patients should not work if they are feeling unwell. “Any stress on a diabetic patient would predispose you to your diabetes going out of control. These people should practice ‘sick day’ guidelines. If you become unwell, you develop…flu-like symptoms, your blood sugar would spike. “The rule is not to stop your diabetic medicine…get in contact with your health professionals for further advice.” Also concerning is the fact that young people who tested positive for the virus in other countries have been seen to develop abnormal clotting due to the virus. “Even young people who do not manifest these (diseases), are being diagnosed with strokes, cardiovascular accidents, because of increased clotting that occurs when one develops a COVID-19 infection.” People with the following conditions are at higher risk of severe COVID-19 complications: - Asthmatics - Chronic lung disease - Diabetes - Serious heart conditions - Chronic kidney disease/Dialysis - Severe obesity - Elderly (65 years and older) - Carehome residents - Immunocompromised - Liver disease Deyalsingh said the Ministry has implemented several measures to reduce the prevalence of non-communicable diseases including the banning of soft drinks at public schools, which he said has reduced soft drink consumption among children by 25 percent. He added that over the past year there was a drop in visits to the Accident and Emergency departments by 1.5 to two percent for people with hypertension and diabetes. Get the latest local and international news straight to your mobile phone for free: DIALYSIS DIABETES HYPERTENSION MINISTRY HEALTH DR ROSHAN PARASRAM DR NEAL BHAGWANDASS TRINIDAD CORONAVIRUS COVID-19 Related articles Comments Share this article Share to FacebookShare to TwitterShare to LinkedInShare to WhatsAppShare to MessengerShare to EmailShare to TelegramShare to More124 Trending Recent News Loop News Theme SECTIONS T&T NewsWorld NewsCOVID-19CarnivalViralEntertainmentLifestyleBusinessSport LOOP NEWS Privacy PolicyComments PolicyAbout UsContact UsSubmit an Article NEWSLETTER Email COPYRIGHT 2017 BY TREND MEDIA | ALL RIGHTS RESERVED Electropages icon Electropages uses cookies to give you the best experience. I'm fine with thisInformation and Settings Electropages logo Home Insights Product News NPI Channels Search Term Magnifying glass icon Tetherless pulse oximeter can monitor COVID-19 patients at home 23-04-2020 | Nordic | Test & Measurement Nordic Semiconductor is meeting demand for its high-end Bluetooth SoC. This lies at the heart of an industry-leading, battery-powered wireless pulse oximeter, the Radius PPG, that was launched last year by Masimo and is now set to join the front-line battle against COVID-19 as part of that company's SafetyNet solution. As the Radius PPG is created to enable tetherless monitoring, it can be used as part of the SafetyNet platform to remotely manage COVID-19 patients at home and conceivably assist hospitals from being overwhelmed by less severe cases. "We didn't originally develop Radius PPG to combat COVID-19," says Bilal Muhsin, chief operating officer, Masimo. "We first and foremost developed it so it could monitor hospital patients accurately, even when the patient is moving, without the inconvenience of a wired connection to a monitor. But it turns out that in the current COVID-19 crisis this tetherless capability, when paired with a secure, cloud-based telehealth platform accessible from a smartphone for patients and from a web-based dashboard for providers, can provide a valuable way to manage COVID-19 patients who do not require hospitalisation. And continue to check them from their homes, allowing hospital beds to be freed up for those who need it. Masimo SafetyNet uses the same Radius PPG tetherless pulse oximeter designed for use in the hospital to provide a remote patient management solution small enough to be worn comfortably and simple enough to be set-up quickly on the patient's smartphone." "Our hearts go out to the brave front line medical and hospital personnel doing their absolute best to cope with the often overwhelming numbers of COVID-19 patients coming through their doors in COVID-19 hotspots around the world," concludes Geir Langeland, Nordic Semiconductor director of sales and marketing. Nordic's latest multiprotocol SoC is its most advanced ultra low power wireless solution. The SoC supports complex Bluetooth LE and other wireless applications that were previously not possible with a single-chip solution. Nordic logo Facebook icon Twitter icon LinkedIn icon Email icon Print icon Related product news Next generation proximity sensors for GAPS and HAPS 22-04-2020 | Test & Measurement Motion detector aids designers in adding different technologies 21-04-2020 | Test & Measurement New sensor solution for ventilators 20-04-2020 | Test & Measurement Cost-effective MEMS sensors give increased performance and reliability 17-04-2020 | Test & Measurement Information Contact Us About Archive Submit PR Advertise Manage newsletter Subscribe Manage Subscription RSS feeds Our apps Apple icon Android icon Social profiles Facebook icon Twitter icon All news & general enquiries: +44 (0)1202 237137 info@electropages.com Copyright © 2020 Electropages Media Ltd Cookie Policy | Privacy Policy Electropages Media logo